J&J MedTech Is Championing the Evolution of PFA

Johnson & Johnson recently announced the European launch of VARIPULSE Pro, the next evolution of its pulsed field ablation (PFA) platform. Highlight the next-gen tech is a new sequence that delivers ablations that are five times faster than the previous sequence while achieving equivalent lesions. The platform also integrates directly with J&J's CARTO 3 system to maintain a familiar workflow. It's a major step forward for a still-evolving technology. Michael Bodner, company group chair of electrophysiology and neurovascular at Johnson & Johnson MedTech, joined Medical Design & Development for a deeper diver into this technology.